286 related articles for article (PubMed ID: 16039868)
41. Evaluation of rapamycin-induced cell death.
Galluzzi L; Morselli E; Kepp O; Vitale I; Younes AB; Maiuri MC; Kroemer G
Methods Mol Biol; 2012; 821():125-69. PubMed ID: 22125064
[TBL] [Abstract][Full Text] [Related]
42. Tubers and tumors: rapamycin therapy for benign and malignant tumors.
Plas DR; Thomas G
Curr Opin Cell Biol; 2009 Apr; 21(2):230-6. PubMed ID: 19237273
[TBL] [Abstract][Full Text] [Related]
43. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
Rao RD; Buckner JC; Sarkaria JN
Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
[TBL] [Abstract][Full Text] [Related]
44. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells.
Rouf MA; Vural I; Renoir JM; Hincal AA
J Liposome Res; 2009; 19(4):322-31. PubMed ID: 19863167
[TBL] [Abstract][Full Text] [Related]
45. Characterization of the FKBP.rapamycin.FRB ternary complex.
Banaszynski LA; Liu CW; Wandless TJ
J Am Chem Soc; 2005 Apr; 127(13):4715-21. PubMed ID: 15796538
[TBL] [Abstract][Full Text] [Related]
46. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling.
Chen J; Fang Y
Biochem Pharmacol; 2002 Oct; 64(7):1071-7. PubMed ID: 12234610
[TBL] [Abstract][Full Text] [Related]
47. TORgeting oncogene addiction for cancer therapy.
Choo AY; Blenis J
Cancer Cell; 2006 Feb; 9(2):77-9. PubMed ID: 16473275
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic potential of target of rapamycin inhibitors.
Easton JB; Houghton PJ
Expert Opin Ther Targets; 2004 Dec; 8(6):551-64. PubMed ID: 15584862
[TBL] [Abstract][Full Text] [Related]
49. mTOR--beyond transplantation.
Young DA; Nickerson-Nutter CL
Curr Opin Pharmacol; 2005 Aug; 5(4):418-23. PubMed ID: 15955739
[TBL] [Abstract][Full Text] [Related]
50. Toward the definition of immunosuppressive regimens with antitumor activity.
Casadio F; Croci S; D'Errico Grigioni A; Corti B; Grigioni WF; Landuzzi L; Lollini PL
Transplant Proc; 2005 Jun; 37(5):2144-7. PubMed ID: 15964362
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of rapamycin in patient with juvenile rheumatoid arthritis.
Foroncewicz B; Mucha K; Paczek L; Chmura A; Rowiński W
Transpl Int; 2005 Mar; 18(3):366-8. PubMed ID: 15730500
[TBL] [Abstract][Full Text] [Related]
52. Rapamycin causes activation of protein phosphatase-2A1 and nuclear translocation of PCNA in CD4+ T cells.
Morrow PW; Tung HY; Hemmings HC
Biochem Biophys Res Commun; 2004 Oct; 323(2):645-51. PubMed ID: 15369799
[TBL] [Abstract][Full Text] [Related]
53. Pilot study: rapamycin in advanced hepatocellular carcinoma.
Schöniger-Hekele M; Müller C
Aliment Pharmacol Ther; 2010 Sep; 32(6):763-8. PubMed ID: 20629977
[TBL] [Abstract][Full Text] [Related]
54. mTOR pathway and mTOR inhibitors as agents for cancer therapy.
Baldo P; Cecco S; Giacomin E; Lazzarini R; Ros B; Marastoni S
Curr Cancer Drug Targets; 2008 Dec; 8(8):647-65. PubMed ID: 19075588
[TBL] [Abstract][Full Text] [Related]
55. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation.
Laschke MW; Elitzsch A; Scheuer C; Holstein JH; Vollmar B; Menger MD
Br J Pharmacol; 2006 Sep; 149(2):137-44. PubMed ID: 16894343
[TBL] [Abstract][Full Text] [Related]
56. Targeting mTOR for cancer treatment.
Rubio-Viqueira B; Hidalgo M
Adv Exp Med Biol; 2006; 587():309-27. PubMed ID: 17163174
[TBL] [Abstract][Full Text] [Related]
57. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.
Cheng H; Force T
Circ Res; 2010 Jan; 106(1):21-34. PubMed ID: 20056943
[TBL] [Abstract][Full Text] [Related]
58. Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus.
Gregory MA; Gaisser S; Lill RE; Hong H; Sheridan RM; Wilkinson B; Petkovic H; Weston AJ; Carletti I; Lee HL; Staunton J; Leadlay PF
Angew Chem Int Ed Engl; 2004 May; 43(19):2551-3. PubMed ID: 15127450
[No Abstract] [Full Text] [Related]
59. mTOR-targeted therapy of cancer with rapamycin derivatives.
Vignot S; Faivre S; Aguirre D; Raymond E
Ann Oncol; 2005 Apr; 16(4):525-37. PubMed ID: 15728109
[TBL] [Abstract][Full Text] [Related]
60. Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.
Cifarelli V; Lashinger LM; Devlin KL; Dunlap SM; Huang J; Kaaks R; Pollak MN; Hursting SD
Diabetes; 2015 May; 64(5):1632-42. PubMed ID: 25576058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
